Nie Y, Sun W, Xiao Z, Ye S. Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor: A case report.
Medicine (Baltimore) 2019;
98:e14060. [PMID:
30653116 PMCID:
PMC6370167 DOI:
10.1097/md.0000000000014060]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
RATIONALE
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is characterized by KIT mutations. Patientsresistant to 1st-line imatinib therapy are usually given sunitinib assecond-line treatment, which provides a median progression-free survival of 8 to 12 months. We report the 1st case of metastatic jejunum GIST with a KIT exon 11 deletion that showed complete response (CR) to sunitinib for more than 3 years.
PATIENT CONCERNS
A 34-year-old man with advanced jejunum GIST was surgically treated upon initial diagnosis, and was histologically found to carry a high recurrence risk. Genetic testing revealed a KIT exon 11 deletion, and adjuvant therapy with imatinib was administered. The imatinib dose was escalated following recurrence in the abdomen, but the mass continued to grow.
DIAGNOSIS
He was diagnosed with abdominal recurrence of GIST based on his medical history and histopathological results.
INTERVENTION
Second-line sunitinib therapy was given.
OUTCOMES
The mass disappeared, and CR was seen following 7 months of sunitinib therapy; this CR was sustained for more than 45 months.
LESSONS
In cases of metastatic jejunum GIST with a KIT exon 11 deletion, sunitinib as second-line therapy can be used to achieve CR for more than 3 years.
Collapse